In cluster-randomized crossover (CRXO) trials, groups of individuals are randomly assigned to one of two or more sequences of alternating treatments. Since clusters serve as their own control, the CRXO design is typically more statistically efficient than the usual parallel-arm design. CRXO trials are increasingly popular in many areas of health research where the number of available clusters is limited. Further, in trials among severely ill patients, researchers often want to assess the effect of treatments on secondary non-terminal outcomes, but frequently in these studies, there are patients who do not survive to have these measurements fully recorded. In this paper, we provide a causal inference framework and treatment effect estimation method for addressing truncation by death in the setting of CRXO trials. We target the survivor average causal effect (SACE) estimand, a well-defined subgroup treatment effect obtained via principal stratification. We propose causal structural assumptions and standard parametric modeling assumptions that together enable estimating the SACE within a Bayesian paradigm. We evaluate the small-sample performance of our proposed Bayesian approach for estimation of the SACE in CRXO trial settings via simulation studies. We apply our method to a previously conducted two-period cross-sectional CRXO study examining the impact of proton pump inhibitors compared to histamine-2 receptor blockers on length of hospitalization among adults requiring invasive mechanical ventilation.

翻译：暂无翻译